Advantages of extended-release metformin in patients with type 2 diabetes mellitus
| Autor: | Serge Jabbour, Barry Ziring |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
endocrine system diseases Physiology Endocrinology Diabetes and Metabolism QD415-436 Hypoglycemia Gastroenterology Biochemistry Medication Adherence Endocrinology Internal medicine Diabetes mellitus medicine Internal Medicine Humans Hypoglycemic Agents QP1-981 In patient Dosing Nutrition and Dietetics business.industry Public Health Environmental and Occupational Health nutritional and metabolic diseases Type 2 Diabetes Mellitus General Medicine medicine.disease Metformin Tolerability Diabetes Mellitus Type 2 Delayed-Action Preparations Extended release business medicine.drug |
| Zdroj: | Ожирение и метаболизм, Vol 9, Iss 1 (2012) |
| ISSN: | 2306-5524 2071-8713 |
| Popis: | Metformin is a first-line pharmacological treatment for patients with type 2 diabetes mellitus because of its favorable overall profile, including its glucose-lowering ability, weight-neutral effects, and low risk of hypoglycemia; however, gastrointestinal (GI) intolerance may limit use in some patients. Extended-release metformin improves GI tolerability, allows once-daily dosing, and is currently available in multiple branded and generic formulations; however, it is more expensive than immediate-release metformin. Maximum plasma metformin concentrations are reached more slowly with the extended-release formulation compared with conventional immediate-release metformin, although both provide similar exposure at a given total daily dose. Extended-release metformin is as effective as immediate-release metformin in patients newly started on metformin and those switched from the immediate-release formulation, with similar weight-neutral effects. Tolerability is generally comparable, although patients switched from the immediate-release formulation--even those switched due to GI intolerance--are often better able to tolerate the extended-release formulation. Based on studies of extended-release formulations in other disease states, metformin extended-release formulation has the potential to improve patient adherence with a simpler dosing regimen and increased tolerability. Increased adherence may result in greater glycemic control, and in turn, improve outcomes and lower health care usage and costs. Extended-release metformin provides an appropriate option for patients with type 2 diabetes mellitus who require several medications to achieve glycemic control or manage comorbid conditions, and for those who have GI intolerance with the immediate-release formulation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|